Amy K Brooks

US Patent:

20090209574, Aug 20, 2009

Filed:

Feb 16, 2009

Appl. No.:

12/371880

Inventors:

Geoffrey Robert Owen - Southlake TX, US
Amy C. Brooks - Burleson TX, US
Lina Bernal-Perez - Fort Worth TX, US
David W. Stroman - Irving TX, US
Joseph J. Dajcs - Fort Worth TX, US

Assignee:

ALCON RESEARCH, LTD. - Fort Worth TX

International Classification:

A61K 31/437
A61K 31/56

US Classification:

514300, 514171

Abstract:

The present invention relates to fluoroquinolone derivatives having enhanced ocular penetration characteristics and/or antimicrobial activity, and to compositions comprising such derivatives. The derivatives and compositions are particularly well suited for treating ophthalmic bacterial infections. The present invention more particularly relates to the discovery that a 2-methyl substitution on a diazabicyclo group attached to a fluoroquinolone ring system produces improved permeability characteristics, and that a 5-amino substitution on a fluoroquinolone ring system results in improved anti-microbial activity.

US Patent:

20110160172, Jun 30, 2011

Filed:

Mar 8, 2011

Appl. No.:

13/043118

Inventors:

Geoffrey Robert Owen - Southlake TX, US
Amy C. Brooks - Burleson TX, US
Lina Bernal-Perez - Fort Worth TX, US
David W. Stroman - Irving TX, US
Joseph J. Dajcs - Fort Worth TX, US

Assignee:

ALCON RESEARCH, LTD. - Fort Worth TX

International Classification:

A61K 31/4709
A61K 31/56
A61K 31/573
A61P 29/00
A61P 31/00
A61P 27/02

US Classification:

514171, 514300

Abstract:

The present invention relates to fluoroquinolone derivatives having enhanced ocular penetration characteristics and/or antimicrobial activity, and to compositions comprising such derivatives. The derivatives and compositions are particularly well suited for treating ophthalmic bacterial infections. The present invention more particularly relates to the discovery that a 2-methyl substitution on a diazabicyclo group attached to a fluoroquinolone ring system produces improved permeability characteristics, and that a 5-amino substitution on a fluoroquinolone ring system results in improved anti-microbial activity.

US Patent:

20120108557, May 3, 2012

Filed:

Jan 13, 2012

Appl. No.:

13/349688

Inventors:

Geoffrey Robert Owen - Southlake TX, US
Amy C. Brooks - Burleson TX, US
Lina F. Bernal-Perez - Fort Worth TX, US
David W. Stroman - Irving TX, US
Joseph J. Dajcs - Fort Worth TX, US

Assignee:

ALCON RESEARCH, LTD. - Fort Worth TX

International Classification:

A61K 31/4709
A61K 31/573
A61P 27/02
A61P 31/00

US Classification:

514171, 514300

Abstract:

The present invention relates to fluoroquinolone derivatives having enhanced ocular penetration characteristics and/or antimicrobial activity, and to compositions comprising such derivatives. The derivatives and compositions are particularly well suited for treating ophthalmic bacterial infections. The present invention more particularly relates to the discovery that a 2-methyl substitution on a diazabicyclo group attached to a fluoroquinolone ring system produces improved permeability characteristics, and that a 5-amino substitution on a fluoroquinolone ring system results in improved anti-microbial activity.

US Patent:

20060257487, Nov 16, 2006

Filed:

May 8, 2006

Appl. No.:

11/430239

Inventors:

Geoffrey Owen - Southlake TX, US
Amy Brooks - Burleson TX, US
Gustav Graff - Cleburne TX, US

International Classification:

A61K 9/14
A61K 31/165

US Classification:

424486000, 514616000

Abstract:

Topical aqueous suspension compositions of sparingly soluble ophthalmic drugs are disclosed. The compositions comprise a combination of a poloxamer or meroxapol surfactant and a glycol tonicity-adjusting agent such as propylene glycol.

US Patent:

20060257486, Nov 16, 2006

Filed:

May 8, 2006

Appl. No.:

11/429736

Inventors:

Geoffrey Owen - Southlake TX, US
Amy Brooks - Burleson TX, US
Gustav Graff - Cleburne TX, US

International Classification:

A61K 9/14

US Classification:

424486000

Abstract:

Topical aqueous suspension compositions of sparingly soluble ophthalmic drugs are disclosed. The compositions comprise a combination of a poloxamine nonionic surfactant and a glycol tonicity-adjusting agent such as propylene glycol.